Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;71(2):171-175.
doi: 10.1097/MPG.0000000000002786.

Polyethylene Glycol Dosing for Constipation in Children Younger Than 24 Months: A Systematic Review

Helisa Rachel  1   2 , Andrew F Griffith  1   2 , Warwick J Teague  1   2   3 , John M Hutson  1   3   4 , Susan Gibb  1   3   5 , Sharon Goldfeld  1   3   6 , Misel Trajanovska  1   3   6 , Sebastian K King  1   2   3   7
Affiliations

Polyethylene Glycol Dosing for Constipation in Children Younger Than 24 Months: A Systematic Review

Helisa Rachel et al. J Pediatr Gastroenterol Nutr. 2020 Aug.

Abstract

Objectives: Evaluate safety and effectiveness of Polyethylene glycol (PEG) for chronic constipation in children aged younger than 24 months. Identify the optimum dose of PEG to manage chronic constipation in children aged younger than 24 months.

Methods: In this systematic review, Embase, Medline Ovid, Pubmed, and the Cochrane Library were searched between January 1, 2000 and February 1, 2019. Studies investigating functional constipation, in which patients younger than 24 months of age were treated with PEG, were considered as potentially eligible for review. Two authors screened the studies against inclusion/exclusion criteria. Study quality was assessed with the PEDro quality assessment, Cochrane risk of bias tool, and/or the Newcastle-Ottawa Scale.

Results: Five studies (2 randomized controlled trials, 3 retrospective chart reviews) satisfied selection criteria (n = 459). All studies employed different dosage categories: mean effective maintenance dose, mean initial dose, mean short-term and long-term dose, and mean daily dose. Dosage regimens were variable, with 0.45 to 1.1 g · kg · day for PEG3350 and 0.48 to 0.65 g · kg · day for PEG4000. Adverse effects were transient across all studies for all types of PEG; these included diarrhea and abdominal pain.

Conclusions: This systematic review provided evidence for a lack of reported side effects from PEG for children aged younger than 24 months. Evidence to establish appropriate dosage regimens does not exist.An infographic accompanying this article can be found at http://links.lww.com/MPG/B839.

PubMed Disclaimer

References

    1. Greenwald BJ. Clinical practice guidelines for pediatric constipation: pediatric constipation. J Am Acad Nurse Pract 2010; 22:332–338.
    1. Baker SS, Liptak GS, Colletti RB, et al. Constipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition [published correction appears in J Pediatr Gastroenterol Nutr 2000;30(1):109]. J Pediatr Gastroenterol Nutr 1999; 29:612–626.
    1. Dupont C, Leluyer B, Maamri N, et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr 2005; 41:625–633.
    1. Treepongkaruna S, Simakachorn N, Pienvichit P, et al. A randomised, double-blind study of polyethylene glycol 4000 and lactulose in the treatment of constipation in children. BMC Pediatr 2014; 14:153.
    1. Voskuijl W, De Lorijn F, Verwijs W, et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004; 53:1590–1594.

Publication types

Substances